Stepan Company (SCL) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The annual meeting is scheduled for April 29, 2025, with voting on four key proposals, including director elections, executive compensation, auditor ratification, and an amendment to the equity incentive plan.
The record date for voting is March 3, 2025, with 22,554,929 shares outstanding, each entitled to one vote per matter.
Proxy materials are available online, and shareholders are encouraged to vote electronically or by mail.
Voting matters and shareholder proposals
Election of two directors, Lorinda A. Burgess and Luis E. Rojo, for three-year terms; both are current directors.
Advisory vote on executive compensation (Say-on-Pay).
Ratification of Deloitte & Touche LLP as independent auditor for 2025.
Approval of the amendment and restatement of the 2022 Equity Incentive Compensation Plan, adding 500,000 shares and extending the plan by 10 years.
Shareholder proposals and director nominations for 2026 must comply with by-law and SEC requirements.
Board of directors and corporate governance
The board is divided into three classes with staggered terms; majority of directors and all committee members are independent.
Board committees include Audit, Compliance, Human Capital and Compensation, and Nominating and Corporate Governance, all composed of independent directors.
Board leadership is separated between Chairman (F. Quinn Stepan, Jr.) and CEO (Luis E. Rojo); Lead Independent Director role transitions from Edward J. Wehmer to Randall S. Dearth.
Annual board and committee performance evaluations are conducted.
Board diversity: 38% women, 13% African American, 13% Hispanic, average age 62, average tenure 11 years.
Latest events from Stepan Company
- Proxy covers director elections, pay practices, auditor ratification, and strong governance.SCL
Proxy filing25 Mar 2026 - Adjusted EBITDA grew 6% to $198.9M; Project Catalyst targets $100M in savings.SCL
Q4 202523 Feb 2026 - Adjusted EBITDA grew 4% in Q2 2024 despite lower net income and significant one-time expenses.SCL
Q2 20242 Feb 2026 - Q3 net income up 88% to $23.6M, EBITDA up 11%, with strong Surfactants and cost savings.SCL
Q3 202417 Jan 2026 - Net income up 42% and EBITDA up 12% on strong surfactant and specialty growth.SCL
Q1 202524 Dec 2025 - Net income up 25% and adjusted EBITDA rose 4%, with Pasadena facility to boost 2025 growth.SCL
Q4 202423 Dec 2025 - Strategic investments and innovation drive growth in key markets, with renewed segment momentum in 2024.SCL
16th Annual Midwest Ideas Conference23 Nov 2025 - Q2 2025 net income rose 19% and adjusted EBITDA grew 8%, led by Polymers and Crop Productivity.SCL
Q2 202516 Nov 2025 - Q3 2025 net income fell 54%, but adjusted EBITDA and free cash flow both increased.SCL
Q3 20255 Nov 2025